Komori
KYORIN Pharmaceutical (4569) · RiskMitigated

Impact of the Fire at the West Japan Distribution Center on Product Supply

First written in FY2022-Q3. 2 of 3 entries say "Mitigated", first in FY2023-Q1. Latest entry: FY2023-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2022-Q3MitigatedFY2023-Q1 – FY2023-Q32022: 220222023: 12023
Same theme, other companies
Supply impact and compensation from the West Japan Distribution Center fireA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3MitigatedAnnual report

    「西日本配送センターにおける火災により被災した委託保管製品に関わる保険差益8億81百万円、及び受取損害賠償金4億01百万円を特別利益として計上し」

    西日本配送センター火災に関して保険差益8億81百万円と受取損害賠償金4億01百万円を計上し、火災影響への金銭的な補填を記載している。
  2. FY2023-Q1MitigatedAnnual report

    「杏林製薬㈱ 西日本配送センターを㈱日立物流西日本 久御山営業所内に開設し、2022年6月9日より出荷を開始いたしました。また上述の通り、この火災により被災した委託保管製品に関わる保険差益8億79百万円を特別利益として計上しました。」

    西日本配送センター火災後、代替となる西日本配送センターを開設して出荷を再開し、被災製品について保険差益8億79百万円を計上した。
  3. FY2022-Q3MaterialisedAnnual report

    「Regarding the impact of the fire that occurred on 29 November 2021 at KYORIN Pharmaceutical Co.,Ltd.’s West Japan Distribution Center, operated by Hitachi Transport System West Japan Co., Ltd. at its Maishima office, we determined that product supply would not be materially affected based on the inventory storage status of KYORIN Pharmaceutical Co.,Ltd. and KYORIN Remedio Co., Ltd.」

    Although a fire occurred at the West Japan Distribution Center, the Group determined from inventory levels that product supply would not be materially affected.
Moved together

"Expansion of the development pipeline and acceleration of new drug development in 3 priority areas" moved the same way as this thread, in the same document, in 2 of its 3 moves.

22222★12345
  1. ★This thread
  2. 1Expansion of the development pipeline and acceleration of new drug development in 3 priority areas2×
  3. 2Expansion of the Generic Pharmaceuticals Business Centered on In-House Sales2×
  4. 3Expanding Product Offerings in Priority Areas through Active Licensing2×
  5. 4Maximizing Uptake of Core Products and Accelerating New Product Uptake2×
  6. 5Efficient Research and Development through Co-Development2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Impact of the Fire at the West Japan Distribution Center on Product Supply | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori